ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Kemas kini terakhir: 6 hari lalu, 11:10AM

207.63

2.34 (1.14%)

  • 1H 1.14%
  • 5H -0.74%
  • 1B -1.48%
  • 6B 7.24%
  • Tahun Ke Tarikh 15.71%
  • 1T 22.28%
  • 5T 174.16%
Penutupan Terdahulu 205.29
Buka 204.43
Jumlah Dagangan 3,081,317
Purata Dagangan (3B) 6,329,994
Modal Pasaran 367,284,453,376
Harga / Pendapatan (P/E TTM) 87.24
Harga / Pendapatan (P/E Ke hadapan) 16.72
Harga / Jualan (P/S) 6.46
Harga / Buku (P/B) 109.22
Julat 52 Minggu
153.58 (-26%) — 218.66 (5%)
Tarikh Pendapatan 25 Apr 2025
Hasil Dividen (DY TTM) 3.03%
Margin Keuntungan 7.59%
Margin Operasi (TTM) 36.66%
EPS Cair (TTM) 2.38
Pertumbuhan Hasil Suku Tahunan (YOY) 5.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -12.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 2,021.97%
Nisbah Semasa (MRQ) 0.660
Aliran Tunai Operasi (OCF TTM) 18.81 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 19.98 B
Pulangan Atas Aset (ROA TTM) 8.49%
Pulangan Atas Ekuiti (ROE TTM) 62.29%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok AbbVie Inc. Menaik Menaik

AISkor Stockmoo

0.1
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ABBV 367 B 3.03% 87.24 109.22
JNJ 369 B 3.24% 26.47 5.39
PFE 130 B 7.36% 16.29 1.48
BMY 122 B 4.03% - 7.42
GSK 70 B 4.54% 23.00 4.47
LLY 663 B 0.73% 62.88 52.04

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.10%
% Dimiliki oleh Institusi 73.94%
227.90227.90195.20195.20162.50162.50129.80129.8097.1097.10Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
153.58 (-26%) — 218.66 (5%)
Julat Harga Sasaran
190.00 (-8%) — 240.00 (15%)
Tinggi 240.00 (Wells Fargo, 15.59%) Beli
Median 217.00 (4.52%)
Rendah 190.00 (UBS, -8.49%) Pegang
Purata 219.22 (5.59%)
Jumlah 7 Beli, 2 Pegang
Harga Purata @ Panggilan 194.48
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wells Fargo 05 Mar 2025 240.00 (15.59%) Beli 211.54
03 Feb 2025 210.00 (1.14%) Beli 190.14
B of A Securities 04 Mar 2025 223.00 (7.41%) Pegang 207.76
BMO Capital 03 Feb 2025 215.00 (3.55%) Beli 190.14
Citigroup 03 Feb 2025 215.00 (3.55%) Beli 190.14
28 Jan 2025 205.00 (-1.26%) Beli 174.81
Guggenheim 03 Feb 2025 214.00 (3.07%) Beli 190.14
Morgan Stanley 03 Feb 2025 239.00 (15.11%) Beli 190.14
Raymond James 03 Feb 2025 220.00 (5.96%) Beli 190.14
Truist Securities 03 Feb 2025 217.00 (4.52%) Beli 190.14
08 Jan 2025 211.00 (1.63%) Beli 178.50
UBS 03 Feb 2025 190.00 (-8.49%) Pegang 190.14
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
31 Mar 2025 Pengumuman AbbVie to Host First-Quarter 2025 Earnings Conference Call
26 Mar 2025 Pengumuman AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
24 Mar 2025 Pengumuman Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
15 Mar 2025 Pengumuman ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
11 Mar 2025 CNBC Ad spending on women's sports more than doubled last year
04 Mar 2025 Pengumuman AbbVie to Present at the Leerink Partners Global Healthcare Conference
03 Mar 2025 Pengumuman AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
28 Feb 2025 Pengumuman AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
26 Feb 2025 Pengumuman AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
14 Feb 2025 Pengumuman AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
13 Feb 2025 Pengumuman AbbVie Declares Quarterly Dividend
12 Feb 2025 Pengumuman Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
12 Feb 2025 Pengumuman AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
12 Feb 2025 Pengumuman AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
07 Feb 2025 Pengumuman U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
06 Feb 2025 Pengumuman Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
05 Feb 2025 Pengumuman Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
31 Jan 2025 Pengumuman AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
29 Jan 2025 Pengumuman Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
24 Jan 2025 Pengumuman Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
23 Jan 2025 Pengumuman AbbVie Completes Acquisition of Nimble Therapeutics
23 Jan 2025 Pengumuman AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
13 Jan 2025 Pengumuman AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
13 Jan 2025 Pengumuman AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
13 Jan 2025 Pengumuman AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
09 Jan 2025 Pengumuman AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07 Jan 2025 Pengumuman CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
Papar semua
Hasil Dividen (DY TTM) 3.03%
Purata Hasil Dividen 5T 3.81%
Nisbah Pembayaran 259.41%
Jangkaan Pembayaran Dividen Seterusnya Aug 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Tunai
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Tunai
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Tunai
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Tunai
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Tunai
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Tunai
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Tunai
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Tunai
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Tunai
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Tunai
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Tunai
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Tunai
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Tunai
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Tunai
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Tunai
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Tunai
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Tunai
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Tunai
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Tunai
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Tunai
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Tunai
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Tunai
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Tunai
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Tunai
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Tunai
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Tunai
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Tunai
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Tunai
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Tunai
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Tunai
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Tunai
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Tunai
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Tunai
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Tunai
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Tunai
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Tunai
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Tunai
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Tunai
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Tunai
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Tunai
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Tunai
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Tunai
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Tunai
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Tunai
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Tunai
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Tunai
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Tunai
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Tunai
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Tunai
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.28 2 1.58
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Papar semua
215.11215.11208.34208.34201.57201.57194.80194.80188.03188.03Mar 20Mar 20Mar 21Mar 21Mar 24Mar 24Mar 25Mar 25Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
8.0008.0006.0006.0004.0004.0002.0002.0000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda